Animal behavioral and neurochemical studies implicate dopaminergic systems in the neurological sequelae induced by estrogen. In the present study, we demonstrated for the first time that MIF-1, a neuropeptide unrelated to classical dopamine agonists, when given prior to, concurrently with, and after 17β-estradiol, antagonized significantly the estrogen-induced increase in the density of dopamine D-2 receptor both in the striatum and the mesolimbic area of male rat brain. The current findings have implications for the prophylactic and therapeutic potential for MIF-1 in extrapyramidal motor disorders caused by estrogen imbalance in humans.
|Original language||English (US)|
|Number of pages||6|
|State||Published - 1987|
Bibliographical noteFunding Information:
This work was supported in part by the Ontario Mental Health Foundation, and the National Institute of Health (NS 20036), USA. We thank Mrs. Sara DeSilvio for her meticulous typing of this manuscript.
- 17β Estradiol
- Density increase
- Dopamine receptor
- Mesolimbic area